Dongzheng Gai

Researcher

University of Arkansas for Medical Sciences

faculty

8 h-index 26 pubs 258 cited

Research Areas

Links

Lab Website

Is this your profile? Verify and claim your profile

OverviewAI-generated summary

Dongzheng Gai's research focuses on understanding the molecular mechanisms underlying cancer development and progression, with a particular emphasis on multiple myeloma. Gai has investigated the role of TRIP13 in protein deubiquitination and its impact on tumor advancement in B cell malignancies. Other studies have explored the potential of bispecific CAR-T cells targeting BCMA and CD24 for controlling multiple myeloma growth, as well as the therapeutic effects of BCMA- and CST6-specific CAR T cells in lysing myeloma cells and suppressing osteolytic lesions. Gai's work also includes examining the mechanisms by which GPR109A mediates the effects of hippuric acid on osteoclastogenesis and bone resorption. Further research has identified CST6 as a suppressor of osteolytic bone disease in multiple myeloma by inhibiting osteoclast differentiation and has investigated the impact of high NEK2 expression in myeloid progenitors on T cell immunity in this context. Additionally, Gai has contributed to the identification of gene signatures that can predict the risk of MGUS progressing to multiple myeloma.

Metrics

h-index: 8
Publications: 26
Citations: 258

Selected Publications

Cystatin M/E Ameliorates Multiple Myeloma-Induced Hyper Osteolytic Bone Resorption (2025) DOI
Cystatin M/E ameliorates bone resorption through increasing osteoclastic cell estrogen influx (2024) DOI
Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth (2024) DOI
High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma (2023) DOI
P-066 BCMA-CAR-T cells with synthetic circuits of CST6 lyse tumor cells and suppress osteolytic lesions in multiple myeloma (2023) DOI
A gene signature can predict risk of MGUS progressing to multiple myeloma (2023) DOI
Decreased bone resorption in Ezh2 myeloid cell conditional knockout mouse model (2023) DOI
A Gene Signature Can Predict Risk of MGUS Progressing to Multiple Myeloma (2023) DOI
A 12 Gene Signature Accurately Predicts Multiple Myeloma Progression from Monoclonal Gammopathy of Undetermined Significance (2022) DOI
CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation (2022) DOI
Deep-Sequencing Can be Used to Reconstruct and Extend Microarray-Based Classification and Risk Stratification for Multiple Myeloma (2021)
NEK2 Inhibition Enhances the Efficacy of PD-1/PD-L1 Blockade in Multiple Myeloma (2021) DOI
Ezh2 mediates epigenetic regulation of osteoclastogenesis and bone remodeling in mice (2021) DOI
GPR109A mediates the effects of hippuric acid on regulating osteoclastogenesis and bone resorption in mice (2021) DOI